Innate Pharma S.A. (IPHA)

Innate Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	12.64	20.12	61.64	57.67	24.7	69.77
Revenue Growth (YoY)	-62.60%	-67.36%	6.88%	133.47%	-64.59%	-18.34%
Gross Profit	12.64	20.12	61.64	57.67	24.7	69.77
Selling, General & Admin	19.9	19.72	18.29	22.44	25.52	18.99
Research & Development	43.42	51.98	56.02	51.66	47	49.71
Other Operating Expenses	-	-	-	41	-	-
Total Operating Expenses	63.33	71.7	74.31	115.1	72.53	68.69
Operating Income	-50.69	-51.58	-12.67	-57.43	-47.83	1.08
Interest Income	9.35	6.08	6.93	4.78	6.34	4.86
Interest Expense	-4.71	-3.98	-1.84	-5.32	-4	-6.76
Total Non-Operating Income (Expense)	4.64	2.1	5.1	-0.55	2.35	-1.91
Pretax Income	-46.05	-49.47	-7.57	-57.97	-45.48	-0.83
Net Income	-46.05	-49.47	-7.57	-58.1	-52.81	-63.98
Earnings From Discontinued Operations	-	-	-	-0.13	-7.33	-63.16
Net Income to Common	-46.05	-49.47	-7.57	-58.1	-52.81	-63.98
Shares Outstanding (Basic)	84	81	80	80	79	79
Shares Outstanding (Diluted)	84	81	80	80	79	79
Shares Change (YoY)	4.16%	0.74%	1.08%	0.77%	0.36%	2.37%
EPS (Basic)	-0.55	-0.61	-0.09	-0.73	-0.83	-0.82
EPS (Diluted)	-0.55	-0.61	-0.09	-0.73	-0.83	-0.82
Free Cash Flow	-41.26	-7.29	-32.91	-19.69	-59.39	-52.67
Free Cash Flow Per Share	-0.49	-0.09	-0.41	-	-0.75	-0.67
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-401.15%	-256.32%	-20.55%	-99.57%	-193.60%	1.55%
Profit Margin	-364.44%	-245.87%	-12.28%	-100.52%	-184.10%	-1.19%
FCF Margin	-326.54%	-36.22%	-53.39%	-34.14%	-240.40%	-75.49%
EBITDA	-49.13	-49.58	-7.58	-12.02	-43.23	57.88
EBITDA Margin	-388.81%	-246.41%	-12.29%	-20.84%	-174.99%	82.95%
EBIT	-50.69	-51.58	-12.67	-57.43	-47.83	1.08
EBIT Margin	-401.15%	-256.32%	-20.55%	-99.57%	-193.60%	1.55%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q